^
Association details:
| Biomarker: | CCNE1 amplification |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | prexasertib (ACR-368) (Chk2 inhibitor, Chk1 inhibitor) + lodapolimab (LY3300054) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 combination study of the CHK1 inhibitor prexasertib (LY2606368) and anti-PD-L1 antibody LY3300054, in patients with high-grade serous ovarian cancer and other advanced solid tumors
Published date:
11/09/2019
Excerpt:
Confirmed partial responses have been observed in 2 patients with CCNE1-amplified HGSOC ongoing for 9 and 10 months, respectively. One additional CCNE-1 amplified HGSOC patient has had prolonged SD for 11 months.
